Introduction: Migraine is a common debilitating neurological disorder affecting a large proportion of the general population. Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, plays a key role in the pathophysiology of migraine, and the development of therapies targeting the anti-CGRP pathway has revolutionized the field of migraine treatment.
Methods: An expert task force of neurologists in the United Arab Emirates (UAE) developed and critically assessed recommendations on the use of CGRP-based therapies in migraine treatment and management in the UAE, based on available published literature. A consensus was reached for each statement by means of an open-voting process, based on a predefined agreement level of at least 60%.
Results: The consensus recommendations advocate the need for guidelines for the appropriate use of CGRP-based therapies by defining patient cohorts and appropriate monitoring of therapeutic response as well as standardizing the initiation, assessment, and cessation of treatment. The consensus recommendations were primarily formulated on the basis of international studies, because of the limited availability of regional and local data. As such, they may also act as guidelines for global healthcare providers.
Conclusions: These are the first consensus recommendations for the UAE that address the use of CGRP-based therapies in the treatment and management of migraine, integrating both clinical evidence and medical expertise to enhance clinical judgment and decision-making.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630270 | PMC |
| http://dx.doi.org/10.1007/s40120-023-00550-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients.
J Virol
September 2024
Mucosal Entry of HIV-1 and Mucosal Immunity, Department of Infection, Immunity and Inflammation, Cochin Institute, Paris, France.
Article Synopsis
- - The study examines the role of calcitonin gene-related peptide (CGRP) in critical COVID-19 patients, finding that levels of CGRP are elevated in both the plasma and lungs during the early stages of infection with SARS-CoV-2.
- - CGRP and its stable analog, SAX, were found to inhibit the infection of bronchial cells by SARS-CoV-2 variants in a dose-dependent manner, suggesting that CGRP plays a protective role against the virus.
- - The research indicates that increased CGRP levels may help in viral clearance by directly inhibiting SARS-CoV-2 replication, which opens potential avenues for CGRP-based therapies in managing COVID-19.
[CGRP: from neuropeptide to the therapeutic target (background and pathophysiology)].
Fortschr Neurol Psychiatr
July 2024
Neurologische Klinik und Poliklinik, LMU Klinikum Campus Grosshadern, Ludwig-Maximilians-Universität München, München, Germany.
Calcitonin gene-related peptide (CGRP) plays a pivotal role in migraine pathophysiology. The importance of CGRP in migraine became evident from numerous clinical studies investigating CGRP levels both interictally and ictally and reports on the efficacy of CGRP-based migraine therapies. In this paper, the above mentioned studies will be presented and the reader will be introduced to the development of CGRP-based medication.
View Article and Find Full Text PDF[Anti-CGRP-based Migraine Medications: A Comprehensive Overview].
Fortschr Neurol Psychiatr
July 2024
Klinik für Neurologie, Charité Universitätsmedizin Berlin, Berlin, Germany.
In the early 1990s, the neuropeptide calcitonin gene-related peptide (CGRP) was identified as a key messenger in the pathophysiology of migraine and emerged as a treatment target, fundamentally transforming our approach to migraine therapy. While previous prophylactic drugs were non-specific and often caused intolerable side effects, the discovery of CGRP marked the advent of a new era in migraine treatment. The two main classes of CGRP-specific migraine treatments are monoclonal antibodies that bind to CGRP or the CGRP receptor, and CGRP receptor antagonists, the so-called gepants.
View Article and Find Full Text PDFAcute Treatment of Migraine: Expert Consensus Statements from the United Arab Emirates (UAE).
Neurol Ther
April 2024
Neurology Department, Rashid Hospital, Dubai, UAE.
Article Synopsis
- Migraines significantly diminish quality of life and everyday activities for affected individuals, leading to increased healthcare costs and disruption in work or school, particularly in the UAE where there's a lack of specific guidelines for acute migraine management.
- A task force of eight UAE neurologists developed expert recommendations for acute migraine treatment, utilizing a Delphi panel of 16 neurologists to reach consensus through a structured survey method.
- The resulting nine consensus statements will serve as a comprehensive guide for healthcare professionals in the UAE, addressing key areas such as treatment goals, timing, response strategies, and safety in combining therapies.
Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE.
Neurol Ther
December 2023
Neurology Department, Rashid Hospital, Dubai, UAE.
Introduction: Migraine is a common debilitating neurological disorder affecting a large proportion of the general population. Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, plays a key role in the pathophysiology of migraine, and the development of therapies targeting the anti-CGRP pathway has revolutionized the field of migraine treatment.
Methods: An expert task force of neurologists in the United Arab Emirates (UAE) developed and critically assessed recommendations on the use of CGRP-based therapies in migraine treatment and management in the UAE, based on available published literature.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!